Editorial
doi: 10.1183/13993003.01700-2021.
Print 2022 Jan.
Is tezepelumab more than just an anti-eosinophil drug?
Affiliations
- PMID: 34972684
- DOI: 10.1183/13993003.01700-2021
Item in Clipboard
Editorial
Is tezepelumab more than just an anti-eosinophil drug?
Eur Respir J.
.
Free article
No abstract available
Conflict of interest statement
Conflict of interest: A. Adatia was supported by the Canadian Institutes of Health Research/Canadian Allergy, Asthma, and Immunology Foundation/AstraZeneca/Allergen NCE Emerging Scientist Award in Allergic Asthma. Conflict of interest: M. Wahab has nothing to disclose. Conflict of interest: I. Satia is currently supported by the E.J. Moran Campbell Early Career Award, Department of Medicine, McMaster Univesity and previously reports grants from the ERS (RESPIRE3 Marie Curie Award), BMA James Trust Award, North West Lung Centre Grant; personal fees and sponsorship to attend meetings from Merck MSD, Genentech, AstraZeneca and GSK, outside the submitted work.
Comment on
-
The effect of tezepelumab on airway hyperresponsiveness to mannitol in asthma (UPSTREAM).Eur Respir J. 2021 Dec 31;59(1):2101296. doi: 10.1183/13993003.01296-2021. Print 2022 Jan. Eur Respir J. 2021. PMID: 34049943 No abstract available.
Similar articles
-
Unusual Secretion of Eosinophil Mediators Induced by Benralizumab.J Investig Allergol Clin Immunol. 2021 Dec 21;31(6):513-515. doi: 10.18176/jiaci.0684. Epub 2020 Mar 2. J Investig Allergol Clin Immunol. 2021. PMID: 33650971 No abstract available.
-
Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma.N Engl J Med. 2021 May 13;384(19):1800-1809. doi: 10.1056/NEJMoa2034975. N Engl J Med. 2021. PMID: 33979488 Clinical Trial.
-
Successful pregnancy in the setting of eosinophil depletion by benralizumab.J Allergy Clin Immunol Pract. 2021 Mar;9(3):1405-1407.e3. doi: 10.1016/j.jaip.2020.11.060. Epub 2020 Dec 13. J Allergy Clin Immunol Pract. 2021. PMID: 33316460 Free PMC article. No abstract available.
-
Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma.Expert Opin Drug Metab Toxicol. 2017 Sep;13(9):1007-1013. doi: 10.1080/17425255.2017.1359253. Epub 2017 Jul 24. Expert Opin Drug Metab Toxicol. 2017. PMID: 28737051 Review.
-
Benralizumab: an anti-IL-5 receptor α monoclonal antibody in the treatment of asthma.Immunotherapy. 2018 Apr;10(5):349-359. doi: 10.2217/imt-2017-0161. Epub 2018 Jan 23. Immunotherapy. 2018. PMID: 29359607 Review.
Cited by
-
Eosinophil-Driven vs. Eosinophil-Associated Severe Asthma: Practical Implications for Target Treatment.Int J Mol Sci. 2025 Feb 18;26(4):1729. doi: 10.3390/ijms26041729. Int J Mol Sci. 2025. PMID: 40004192 Free PMC article. Review.
-
Baseline Characteristics of Patients Enrolled in Clinical Trials of Biologics for Severe Asthma as Potential Predictors of Outcomes.J Clin Med. 2023 Feb 15;12(4):1546. doi: 10.3390/jcm12041546. J Clin Med. 2023. PMID: 36836079 Free PMC article. Review.
-
Tezepelumab: patient selection and place in therapy in severe asthma.J Int Med Res. 2024 Apr;52(4):3000605241246740. doi: 10.1177/03000605241246740. J Int Med Res. 2024. PMID: 38676539 Free PMC article. Review.
-
Challenges in severe asthma: Do we need new drugs or new biomarkers?Front Med (Lausanne). 2022 Sep 27;9:921967. doi: 10.3389/fmed.2022.921967. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36237537 Free PMC article. Review.
-
Novel Biological Therapies for Severe Asthma Endotypes.Biomedicines. 2022 May 4;10(5):1064. doi: 10.3390/biomedicines10051064. Biomedicines. 2022. PMID: 35625801 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
